Watson Pharmaceuticals Inc. Jan. 23 announced that it has completed the acquisition of Belgium-based Uteron Pharma SA for $150 million in cash up front, and up to $155 million in potential milestone payments.
Subsequently, Watson said it is changing its name to Actavis Inc., following its purchase of Actavis Group in 2012.
Uteron Pharma is a development-based company dedicated to female health care, said Watson, which is based in Parsippany, N.J. It has a diversified portfolio of innovative products in different stages of development.
The acquisition of Uteron expands Watson’s Global Brands pipeline of women’s health products, including two potential ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.